Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Merck (NYSE:MRK) recently initiated the IDeate-Prostate01 phase 3 trial, dosing the first patient for its investigational drug ifinatamab deruxtecan, aimed at treating metastatic castration-resistant ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Johnson & Johnson is an impeccable dividend stock with a streak of 63 consecutive dividend raises. The company's long history ...

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: ...

Medical Tech Stock Aethlon Medical (Nasdaq: AEMD) Treats Second Patient in Australian Hemopurifier Cancer Trial Poster Presentation Reviews the Hemopu ...

Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T ...

SAN ANTONIO — Finding out you have a deadly disease is never a pleasant experience, But if you have a good support system and the right information about your illness, the direction you go could save ...

In this video, Susana M. Campos, MD, MPH, discusses results from a phase 2 trial of pembrolizumab and lenvatinib for patients with recurrent or persistent clear-cell ovarian cancer.Findings from the ...

Pharmaceutical giant Merck (MRK) received approval from the US Food and Drug Administration (FDA) to use Keytruda to treat head and neck cancer. Shares of American oil producers, namely Occidental ...